Vascular News and Research

RSS

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that in collaboration with OXiGENE, Professor Gordon Rustin and colleagues from the Mount Vernon Cancer Research Centre, UK and other institutions in the United Kingdom, reported positive final data from an investigator-sponsored Phase 1 study of OXi4503 in patients with solid tumors.

7 Jun 2010

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

W. L. Gore & Associates (Gore) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market a 45 mm diameter version of the GORE® TAG® Thoracic Endoprosthesis for treatment of aneurysms of the descending thoracic aorta. The larger diameter device allows treatment of TAAs with proximal and distal neck diameters ranging from 37 - 42 mm and is now available for commercial use in the U.S.

7 Jun 2010

MiMedx' HydroFix Vaso Shield receives FDA clearance for additional thicknesses and sizes

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has received notification by the FDA that the Company's proprietary device, HydroFix™ Vaso Shield, has received 510(k) clearance for additional thicknesses and sizes.

7 Jun 2010

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

VIVUS, Inc. today announced positive results from the phase 3 REVIVE-Diabetes (TA-302) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in men with type 1 and type 2 diabetes. The REVIVE-Diabetes study met all three primary endpoints across the two doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score.

7 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.

7 Jun 2010

OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

Researcher calls stroke specialists to further knowledge and understanding of stroke

To cope with the projected growth in the incidence of strokes in Canada, the public may need to take on roles traditionally performed by healthcare specialists, according to a leading Canadian stroke researcher.

7 Jun 2010

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.

5 Jun 2010

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Biomet, a global leader in the manufacture of orthopedic and biotechnology products, announced today that its subsidiary, Biomet Biologics, has enrolled the first subject into its multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial for critical limb ischemia (CLI).

5 Jun 2010

Too much weight in pregnancy may lead to future heart risks in offspring

Researchers have uncovered evidence to show that piling on too many pounds in pregnancy may lead to future heart risks in the child.

4 Jun 2010

Advanced applications of Nanoflex technology to be presented at New Cardiovascular Horizons Meeting

ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.

4 Jun 2010

New therapy mounts double-barreled attack on leukemia, report UF researchers

A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, University of Florida researchers report.

4 Jun 2010

NORTHSTAR Health System purchases Toshiba's Aplio MX ultrasound system

NORTHSTAR Health System, a rural critical-access health care system in Iron River, Mich., recently completed an $18 million renovation that included upgrading its medical imaging technology. To provide the latest in ultrasound imaging technology to its patient population and expand its diagnostic capabilities, NORTHSTAR Health System purchased Toshiba America Medical Systems, Inc.'s Aplio MX ultrasound system, a compact system that offers premium clinical performance and high-end features at an affordable price point.

3 Jun 2010

Advanced CT scanner allows rapid organ imaging, reduces radiation exposure

UT Southwestern Medical Center is the first site in North Texas to launch the next generation in CT scanners, which allow doctors to image an entire organ in less than a second or track blood flow through the brain or to a tumor - all with less radiation exposure to patients.

3 Jun 2010

Patients at greatest risk of post-PCI bleeding least likely to receive bleeding avoidance strategies

In a study that included data from more than 1.5 million patients, use of vascular closure devices and the anticoagulant bivalirudin were associated with significantly lower bleeding rates for patients following a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study in the June 2 issue of JAMA. The researchers also found that patients who may benefit most from these treatments, those at greatest risk of bleeding, were least likely to receive them.

2 Jun 2010

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.

2 Jun 2010

Texas Heart Institute at St. Luke's Episcopal Hospital performs 1000th carotid artery stent procedure

The Texas Heart Institute (THI) at St. Luke's Episcopal Hospital has announced another major milestone in improved patient care, after performing its 1000th carotid artery stent procedure. Carotid artery stenting (CAS) has emerged as a less invasive treatment for stroke-causing blockages in the carotid artery, meaning patients generally have fewer risks for complications, shorter hospital stays and recovery times and less expense.

2 Jun 2010

Platelets play important role in cerebral malaria: Research

Scientists are making strides against cerebral malaria, a fatal form of malaria in children that can ravage the brain and is extremely difficult to treat. New research points to platelets - known for their role in blood clotting - as playing an important role in the disease, stimulating the immune system and turning on molecules that increase inflammation. The inflammation leads to the obstruction of blood vessels in the brain, causing brain damage similar to that seen with a stroke.

2 Jun 2010

Vascular News and Research

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

MiMedx' HydroFix Vaso Shield receives FDA clearance for additional thicknesses and sizes

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO

Researcher calls stroke specialists to further knowledge and understanding of stroke

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Too much weight in pregnancy may lead to future heart risks in offspring

Advanced applications of Nanoflex technology to be presented at New Cardiovascular Horizons Meeting

New therapy mounts double-barreled attack on leukemia, report UF researchers

NORTHSTAR Health System purchases Toshiba's Aplio MX ultrasound system

Advanced CT scanner allows rapid organ imaging, reduces radiation exposure

Patients at greatest risk of post-PCI bleeding least likely to receive bleeding avoidance strategies

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

Texas Heart Institute at St. Luke's Episcopal Hospital performs 1000th carotid artery stent procedure

Platelets play important role in cerebral malaria: Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News